Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) (CLAVELA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Clavis Pharma
ClinicalTrials.gov Identifier:
NCT01147939
First received: April 14, 2010
Last updated: September 20, 2013
Last verified: September 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2013
  Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: September 12, 2013
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):